Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer

Natsuko Satomi-Tsushita, Akihiko Shimomura, Juntaro Matsuzaki, Yusuke Yamamoto, Junpei Kawauchi, Satoko Takizawa, Yoshiaki Aoki, Hiromi Sakamoto, Ken Kato, Chikako Shimizu, Takahiro Ochiya, Kenji Tamura

Research output: Contribution to journalArticle

Abstract

The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.

Original languageEnglish
Article numbere0222024
JournalPloS one
Volume14
Issue number9
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

eribulin
MicroRNAs
microRNA
metastasis
breast neoplasms
Breast Neoplasms
prediction
Serum
Neoplasm Metastasis
biomarkers
Biomarkers
anthracyclines
taxanes
Anthracyclines
Microarrays
Area Under Curve
sampling
Logistics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Satomi-Tsushita, N., Shimomura, A., Matsuzaki, J., Yamamoto, Y., Kawauchi, J., Takizawa, S., ... Tamura, K. (2019). Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PloS one, 14(9), [e0222024]. https://doi.org/10.1371/journal.pone.0222024

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. / Satomi-Tsushita, Natsuko; Shimomura, Akihiko; Matsuzaki, Juntaro; Yamamoto, Yusuke; Kawauchi, Junpei; Takizawa, Satoko; Aoki, Yoshiaki; Sakamoto, Hiromi; Kato, Ken; Shimizu, Chikako; Ochiya, Takahiro; Tamura, Kenji.

In: PloS one, Vol. 14, No. 9, e0222024, 01.01.2019.

Research output: Contribution to journalArticle

Satomi-Tsushita, N, Shimomura, A, Matsuzaki, J, Yamamoto, Y, Kawauchi, J, Takizawa, S, Aoki, Y, Sakamoto, H, Kato, K, Shimizu, C, Ochiya, T & Tamura, K 2019, 'Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer', PloS one, vol. 14, no. 9, e0222024. https://doi.org/10.1371/journal.pone.0222024
Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S et al. Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. PloS one. 2019 Jan 1;14(9). e0222024. https://doi.org/10.1371/journal.pone.0222024
Satomi-Tsushita, Natsuko ; Shimomura, Akihiko ; Matsuzaki, Juntaro ; Yamamoto, Yusuke ; Kawauchi, Junpei ; Takizawa, Satoko ; Aoki, Yoshiaki ; Sakamoto, Hiromi ; Kato, Ken ; Shimizu, Chikako ; Ochiya, Takahiro ; Tamura, Kenji. / Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer. In: PloS one. 2019 ; Vol. 14, No. 9.
@article{55100d7d05404b09afdbb69e5406b1b7,
title = "Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer",
abstract = "The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.",
author = "Natsuko Satomi-Tsushita and Akihiko Shimomura and Juntaro Matsuzaki and Yusuke Yamamoto and Junpei Kawauchi and Satoko Takizawa and Yoshiaki Aoki and Hiromi Sakamoto and Ken Kato and Chikako Shimizu and Takahiro Ochiya and Kenji Tamura",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0222024",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer

AU - Satomi-Tsushita, Natsuko

AU - Shimomura, Akihiko

AU - Matsuzaki, Juntaro

AU - Yamamoto, Yusuke

AU - Kawauchi, Junpei

AU - Takizawa, Satoko

AU - Aoki, Yoshiaki

AU - Sakamoto, Hiromi

AU - Kato, Ken

AU - Shimizu, Chikako

AU - Ochiya, Takahiro

AU - Tamura, Kenji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.

AB - The identification of biomarkers for predicting the responsiveness to eribulin in patients with metastatic breast cancer pretreated with an anthracycline and a taxane remains an unmet need. Here, we established a serum microRNA (miRNA)-based prediction model for the emergence of new distant metastases after eribulin treatment. Serum samples were collected from metastatic breast cancer patients prior to eribulin treatment and comprehensively evaluated by miRNA microarray. The prediction model for estimating eribulin efficacy was established using the logistic LASSO regression model. Serum samples were collected from 147 patients, of which 52 developed at least one new distant metastasis after eribulin monotherapy and 95 did not develop new distant metastases. A combination of eight serum miRNAs (miR-4483, miR-8089, miR-4755-3p, miR-296-3p, miR-575, miR-4710, miR-5698 and miR-3160-5p) predicted the appearance of new distant metastases with an area under the curve of 0.79, sensitivity of 0.69 and specificity of 0.82. The serum levels of miR-8089 and miR-5698 were significantly associated with overall survival after the initiation of eribulin treatment. The present study provides evidence that serum miRNA profiling may serve as a biomarker for the responsiveness to eribulin and for predicting the development of new distant metastases in metastatic breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=85071755099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071755099&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0222024

DO - 10.1371/journal.pone.0222024

M3 - Article

C2 - 31483849

AN - SCOPUS:85071755099

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - e0222024

ER -